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One of the largest impediments for commercial swine production is the presence of
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), a devastating RNA
viral infection that is responsible for over $1 billion in loss in the U.S. annually. The
challenge with combating PRRSV is a combination of the effect of an extraordinary rate
of mutation, the ability to infect macrophages, and subversion of host immune response
through a series of actions leading to both immunomodulation and immune evasion.
Currently there are a handful of commercial vaccines on the market that have been
shown to be effective against homologous infections, but struggle against heterologous
or mixed strain infections. However, vaccination is the current best strategy for combating
PRRSV, making research into new vaccine technology key. To address these issues
with PRRSV and host antiviral functions a novel modified-live vaccine (MLV) able to
stimulate known antiviral interferons was created and examined for its ability to potentiate
effective immunity and better protection. Here, we examine gene expression in the liver
of pigs vaccinated with our novel vaccine, given the liver’s large role in antiviral responses
and vaccine metabolism. Our study indicated that pigs administered the novel vaccine
experience homeostatic gene expression consistent with less inflammation and T-cell
depletion risk than pigs administered the commercial vaccine.
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INTRODUCTION

The original vaccine challenge study used outbred pigs (5-weekold, n = 10/group).

Growing populations can only be sustained by the availability
of healthy, abundant, and affordable food. Safeguarding these
supplies requires maintaining herds in the face of established
and emerging pathogens. One of the largest impediments to
this for commercial swine production is Porcine Reproductive
and Respiratory Syndrome Virus (PRRSV), a devastating RNA
viral infection that is responsible for over $1 billion in
loss in the U.S. annually (1, 2). The virus exists as two
separate types, PRRSV-1 and PRRSV-2, originally named for the
geographic regions in which they originated (3). The challenge
with combating PRRSV is a combination of the effect of an
extraordinary rate of mutation, the ability to infect macrophages,
and subversion of host immune response through a series
of actions leading to both immunomodulation and immune
evasion (4, 5). PRRSV’s ability to suppress interferon signaling
compromises the antiviral response. Available commercial
vaccines protect animals against homologous infections but
provide less protection than heterologous or mixed strain
infections (6, 7). Nonetheless, vaccination remains the best
available strategy for combating PRRSV. Research into new
vaccine technology may offer tools to offset anticipated viral
adaptation to evade the host immune system, given the selective
pressures arising from widespread vaccine use throughout the
swine industry. To address these issues with PRRSV and
host antiviral functions, we evaluated a novel modified-live
vaccine (MLV) able to stimulate known antiviral interferons
for its ability to potentiate effective immunity and better
protection. Clinical studies of the vaccine prototype showed
efficacy comparable to a commercially available PRRSV vaccine.
Here, we examine gene expression in the liver of unvaccinated
and vaccinated pigs treated with our novel or commercial
MLV vaccine. The porcine liver plays a role in the ability to
mount an immune response against pathogens, is affected by
the vaccine’s metabolism, and is large source of monocytic cells
at various stages of the porcine life cycle. Monocytic cells in
the form of macrophages are the cells which PRRSV infect,
and though the liver is a substantial producer of monocytic
cells, very little is known if the organ acts as a reservoir of the
virus (8–10).

Experimental Design, Animals, and Sample
Collection
This study design employed four of the eight treatment groups
used in the clinical study of the vaccines effectiveness to
protect pigs infected with the NADC-34 strain of PRRSV.
The four treatments were: (a) commercial PRRSV vaccine
Ingelvac PRRS R ATP (MLV-ATP), (b) ARS-novel vaccine
(MLV-129), Sham-challenge (positive control), and Sham-No
challenge (Negative control). Control groups were given a sham
vaccination of cell culture medium at the beginning of the clinical
study in concert with the vaccine treatment groups (-42 days preinfection); all groups were challenged with a PRRSV dose of 2
ml/pig IM at 1 × 104 TCID50/ml (except the negative control
group which was given a sham challenge of cell culture medium).
A total of 5 pigs (n = 5/group) were randomly selected from the
four treatment groups at 14 days post infection (dpi) and had
liver tissue harvested for transcriptomic analysis. This timepoint
coincided with the end of the vaccine trial. Vaccinated animals
were treated with 2 ml/pig of either the commercial or novel
vaccine, which was administered through intramuscular shot.
Pigs in all treatment groups were monitored for symptoms of
illness pre and post inoculation. All animals were monitored for
temperature daily and was compiled weekly. Animal weight was
also observed and recorded weekly. Additional evaluations of the
treatment of all treatment groups were examined and recorded
daily for temperature (◦ C) using a subdermal chip. The threshold
for determining if an animal was experiencing a febrile response
was set at 40◦ C (104 F◦ ). Animals were examined weekly for
individual weight gain. Weight was measured in pounds and
values averaged within treatment group over the time course of
the study. Serology was performed on serum samples by ELISA to
measure the presence of host antibodies in response to the PRRS
viral challenge. Detection was based on mean S/P ratio within
treatment groups for days−42 (vaccination), 0 (challenge), and
14 (necropsy). Positive antibody response was based on S/P ratios
≥0.4 as the cut-off.

Sequencing, Quality Control, and Mapping
Representative samples of liver tissue were extracted from
several locations within the liver and combined at 14 dpi.
Per the method described in Fleming et al. (5) total RNA
was extracted, and quality was measured using an Agilent
bioanalyzer (RIN 3.4-9). Library preparation and sequencing
were performed by the Iowa State University Genomics
′
center using the 3 Quantseq fwd kit and the Illumina
Hiseq 4000 to produce twenty 100 bp single-end reads.
We analyzed sequences using the following tools present
at usegalaxy.org (11) and following the method used in
Fleming et al. (5) with the following changes and software
updates. Quality control was performed using fastp Galaxy
Version 0.19.5+galaxy1 and FastQC (12) to examine raw
read data, remove adapters, and reads with a phred score
below 30. Alignment to the Sscrofa 11.1 reference genome
was carried out using Hisat2 version 2.1.0+galaxy5 (13) set to

MATERIALS AND METHODS
Vaccine Design
Our work was governed by the National Institutes of Health guide
for the care and use of Laboratory animals (NIH Publications
No. 8023, revised 1978). The pCMV-P129 infectious cDNA
clone was constructed from the virulent PRRSV-2 (Linage 8)
field virus P129, isolated in Indiana in 1995. The infectious
clone pKermit (Zoetis) (4) contains the GFP gene within
an additional dedicated sgRNA expression cassette. The GFP
gene was replaced with genes encoding a cohort of optimized
antiviral interferons (IFNs) of different sub-types. The IFN
cohort-expressing virus (PRRSV-P129-IFNmix) was examined
with and without an adjuvant whilst being compared to the
commercial Ingelvac PRRS R ATP (MLV-ATP) MLV vaccine.
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TABLE 1 | MLV-ATP GO terms related to immunity, stress, and homeostasis in
porcine liver.
Term name

default parameters for forward strand alignment. Raw counts
were generated using FeatureCounts (14) and the Ensembl
Sscrofa11.1.104 GTF file. The FeatureCounts tool was set to
default parameters. Differential gene expression (DEG) was
identified using DeSeq2 version 2.11.40.6 (15). The parameters
were set to use poscounts for the estimate SizeFactors to
account for genes with zero counts and the fit type was
set to local with all other parameters tuned to default. We
sought evidence for differentially expressed genes (DEGs) with
a false discovery rate (FDR) ≤ 0.1 and with no minimum
threshold for log2fc up or down regulation. Gene ontology
(GO) and Pathway analysis were conducted using software
from gProfiler (16) and used an FDR of ≤ 0.05 to establish
significance. We also used annotation and pathway information
from homologous human genes in Ensembl, NCBI, Uniprot, and
KEGG (17–20).

MLV-129p-IFNmix vs. Sham-PRRSV
(Vaccinated and Challenged Groups vs.
Non-vaccinated and Challenged)
Analysis of the MLV-129p-IFNmix vaccinated pigs vs. nonvaccinated pigs (Sham-PRRSV) at 14 dpi yielded a total of 197
differentially expressed genes (122 upregulated in the vaccinated
pigs, 75 downregulated) in the liver after statistical cut-off was
(FDR≤ 0.1) applied (Supplementary Table 1). Transcriptomic
analysis of the commercial vaccine (MLV-ATP) vs. the ShamPRRSV group returned a total of 363 DEGs (187 upregulated,
176 downregulated) (Supplementary Table 2). Venn diagram
analysis of the DEGs list for both vaccine groups displayed only
a moderate number of overlapping genes (n = 96), however
the number of uniquely differential expressed differed greatly
between the vaccinated animals; giving the first indication that
the vaccines diverged in molecular impact on the host liver
(Figure 1).
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FIGURE 1 | Venn diagram of statistically significant gene lists for
MLV-129p-IFNmix and MLV-ATP vs. Sham-PRRSV. Genes were considered
significant with FDR of ≤ 0.1.
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TABLE 2 | MLV-129p-IFNmix GO terms related to immunity, stress, and homeostasis in porcine liver.
Term name

Term ID

FDR

Oxoacid metabolic process

GO:0043436

1.82E−04

Negative regulation of interleukin-2 production

GO:0032703

3.59E−04

Negative regulation of T cell activation

GO:0050868

6.88E−04

Regulatory T cell differentiation

GO:0045066

7.47E−04

Immune system process

GO:0002376

1.32E−03

REAC:R-SSC-211859

1.33E−03

Macrophage migration

GO:1905517

1.98E−03

Regulation of immune system process

GO:0002682

3.01E−03

Negative regulation of T cell proliferation

GO:0042130

3.18E−03

Negative regulation of leukocyte activation

GO:0002695

3.18E−03

Regulation of interleukin-2 production

GO:0032663

4.08E−03

Interleukin-2 production

GO:0032623

4.08E−03

Complement and coagulation cascades

KEGG:04610

4.33E−03

Increased inflammatory response

HP:0012649

4.61E−03

Regulation of regulatory T cell differentiation

GO:0045589

5.12E−03

Phagosome

KEGG:04145

5.96E−03

Negative regulation of leukocyte proliferation

GO:0070664

7.03E−03

Regulation of macrophage migration

GO:1905521

7.79E−03

CD4-positive, CD25-positive, alpha-beta regulatory T cell
differentiation

GO:0002361

9.78E−03

Biological oxidations

MAPK cascade

GO:0000165

1.43E−02

Negative regulation of immune effector process

GO:0002698

1.43E−02

Negative regulation of humoral immune response

GO:0002921

1.48E−02

T cell proliferation

GO:0042098

1.93E−02

Negative regulation of lymphocyte differentiation

GO:0045620

2.07E−02

Regulation of T cell activation

GO:0050863

2.36E−02

Regulation of immune response

GO:0050776

2.57E−02

Response to stress

GO:0006950

2.95E−02

Neutrophil extracellular trap formation

KEGG:04613

2.97E−02

REAC:R-SSC-2262752

3.51E−02

T cell activation

GO:0042110

3.64E−02

Positive regulation of MAPK cascade

GO:0043410

3.66E−02

REAC:R-SSC-2132295

4.13E−02

Cellular responses to stress

MHC class II antigen presentation
Complement component C5a signaling pathway

GO:0038178

4.32E−02

Mononuclear cell proliferation

GO:0032943

4.32E−02

Lymphocyte proliferation

GO:0046651

4.32E−02

Regulation of innate immune response

GO:0045088

4.96E−02

Differential Gene Expression Involved in
Biological Pathways of Vaccine Treatment
Groups

the statistically significant terms present between both vaccinated
groups. Analysis of the genes list of being differentially expressed
in the MLV-129p-IFNmix also elucidated this vaccine’s impact
on viral immune response to PRRSV in the liver. The MLV129p-IFNmix group included fewer differentially expressed genes
related to inflammation and stress: 6 such genes are related to the
human disease phenotype term increased inflammatory response
(HP:0012649). The MLV-129p-IFNmix displayed a total of n =
8 genes involved in the cellular response to stress (REAC:RSSC-2262752), however, three of these genes were unannotated
loci. The MLV-129p-IFNmix treated group also displayed more
GO terms related to negative regulation of immune response
pathways, while also displaying differential expression of multiple

Examination of the list of genes being differentially expressed in
the commercial MLV-ATP revealed observations related to the
host response to PRRSV. The over-represented genes showed
that the commercial vaccine stimulated acute inflammatory
response (GO:0006954): nine of fourteen such genes were
upregulated. Additionally, many upregulated genes were ascribed
to the cellular response to stress (n = 24) (GO:0033554),
homeostatic process (n = 26) (GO:0042592), and a human
disease phenotype term Abnormal homeostasis (HP:0012337) (n
= 31) (Table 1). These results were unique to MLV-ATP among
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2 (ALPK2) involved apoptotic regulation and mostly cardiac
related functions, but also a negative regulator of the WNT
signaling pathway (18, 22).

T-cell and macrophage related pathways. The GO terms for MLV129p-IFNmix included differential expression across innate,
humoral, and adaptive immunity which was not observed with
the group treated with the commercial vaccine (Table 2).

DISCUSSION
Unique Genes and Pathways of Interest
Expressed by MLV-129p-IFNmix

MLV-129p-IFNmix May Hasten
Complement and Adaptive Immune
Activation to PRRSV Infection Through
Humoral-Mediated Expression

We endeavored to characterize the immune response in the
livers of challenged pigs who had been vaccinated with a novel
PRRSV vaccine. The Venn diagram depicted that there were
98 genes uniquely differentially expressed in pigs administered
MLV-129p-IFNmix. We explored gene function using porcine
and human annotations to determine key up and down regulated
genes of biological interest (Table 3). Many of the genes in
the list are natively expressed in uninfected porcine liver and
lung at detectable levels (18). Some key upregulated genes of
interest included the most overexpressed gene in the MLV129p-IFNmix analysis, CD209 molecule (CD209), a known
receptor for PRRSV (9, 21). The gene is an innate and adaptive
immunity C-type lectin receptor involved in recognizing various
viral pathogens, regulating virus life cycles, and promoting
T-cell proliferation. In addition to CD209, a small group of
other CD markers, CD9 molecule (CD9) and CD302 molecule
(CD302) were also upregulated as a cluster unique to MLV-129pIFNmix (18, 22). Other genes of biological interest overexpressed
in the liver included cytochrome P450 family 2 subfamily R
member 1 (CYPR2R1) a gene with ubiquitous porcine liver
and lung expression that in humans is known to act as a
catalyst for drug metabolism and human Vitamin D metabolism
(18, 22). Some of the genes of interest interact with the host
immune system through anti-inflammatory, macrophage, and
immune effector actions. Genes falling into this group included
TAFA chemokine like family member 4 (TAFA4), which has
immunoregulatory activity involved in macrophage chemotaxis
and increased ROS release; acid phosphatase 5, tartrate resistant
(ACP5) a negative regulator of inflammatory responses, IL-1B,
and IL-12; killer cell lectin like receptor G1 (KLRG1) a killer and
T cell inhibitor involved in innate and adaptive immune system
immunoregulatory action; and MHC class II, DO beta (HLADOB) an antigen presenting negative regulator and positive Tcell regulator in humans (18, 22). The study also produced
downregulated genes of interest; however, they were fewer in
number. Some of the downregulated genes have a lower natural
expression in uninfected pigs due to liver tissue specificity,
however even native genes involved in normal host functioning
were observed to be down regulated such as fatty acid desaturase
1 (FADS1) involved in the metabolism of inflammatory lipids
and T-cell cytokine production (18, 22) which may possibly link
to liver metabolism effects. Other genes of interest included:
lymphocyte activating 3 (LAG3) an inhibitory immune receptor
that is part of the MHC class II adaptive immune system
responses. The effect of this gene is far-reaching and may prove to
be of great interest due to its involvement in negative regulatory
actions. Other genes of interest included doublecortin like kinase
1 (DCLK1) involved in viral responses and is a negative regulator
of protein localization to the nucleus in humans and alpha kinase

Frontiers in Veterinary Science | www.frontiersin.org

The results indicated interplay between MLV-129p-IFNmix and
unique DEGs CD209, A2M, HLA-DOB, and other upregulated
genes shared by both treatment groups involved in the
complement cascade (Supplementary Tables 1, 2). The gene
CD209 acts as a C-type lectin receptor (CLR) capable of patternrecognition of PRRSV (23). It is possible that the observed
overexpression of CD209 stimulates antigen presentation to Tcells, helping induce adaptive immune reactions. Additionally, as
a lectin receptor CD209 plays a role in the complement cascade
which supports the transition to adaptive immune functions.
Multiple genes involved in both innate and adaptive immune
function suggest that the novel vaccine engender quicker
adaptive immune system recognition, reducing the cellular and
physical stress of the host-pathogen interaction (24, 25).

MLV-129p-IFNmix Promotes Negative
Regulation of Processes That May Bolster
Immune Response to PRRSV
Pigs administered the novel vaccine exhibited changes in
several negative regulatory processes and molecular functions
(Table 2). The range of these pathways were centered around
activation and proliferation of T-cells and leukocytes. The
genes involved in these responses present in our study are
mostly upregulated, pointing to a relaxing of the immune
response characteristic of the innate arm of the porcine
immune response. The preponderance of negative regulation
at 14 dpi in the novel vaccine group was observable at both
the pathway and gene level involving differential expression
spanning both directions. The action of MLV-129p-IFNmix
shows promise related to immune/T-cell exhaustion. Although
T-cell exhaustion more commonly results from prolonged
chronic infections, the abbreviated maturation experienced by
commercial pigs could make a PRRSV infection essentially a
lifelong infection. T-cell exhaustion risks depleting memory Tcells, severely handicapping the immune response. One of the
first indicators of this is thought to be negative regulation of
interleukin 2 (IL-2) (26). Here, of four genes involved in the
negative regulation of interleukin-2 production (GO:0032703),
three were downregulated in pigs receiving the novel vaccine
(Table 2). One of these (LAG3) was unique to the novel vaccine’s
DEG list. Therefore, the novel vaccine may stimulate a better
genomic-mediated immune response in the liver, reducing viral
loads at 14 dpi. The gene LAG3 is an example of this. Its
downregulation may affect negative regulatory processes that
include IL-2 production and Treg cell differentiation. Recent
studies of human LAG3 gene action suggest a possible role
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TABLE 3 | Unique genes differentially expressed by MLV-129p-IFNmix.
Ensembl ID

Gene name

Description

LOG2 FC

ENSSSCG00000013579

CD209

CD209 molecule

1.44

ENSSSCG00000000660

A2M

Alpha-2-macroglobulin

1.00

ENSSSCG00000037762

TBX1

T-box transcription factor 1

0.94

ENSSSCG00000021724

KIF19

Kinesin family member 19

0.94

ENSSSCG00000013389

CYP2R1

Cytochrome P450 family 2 subfamily R member 1

0.88

ENSSSCG00000032282

ACP5

Acid phosphatase 5, tartrate resistant

0.86

ENSSSCG00000023498

HSPB6

Heat shock protein family B (small) member 6

0.81

ENSSSCG00000033199

TAFA4

TAFA chemokine like family member 4

0.81

ENSSSCG00000011609

FBLN2

Fibulin 2

0.79

ENSSSCG00000040461

CDKN1C

Cyclin dependent kinase inhibitor 1C

0.79

ENSSSCG00000000663

KLRG1

Killer cell lectin like receptor G1

0.77

ENSSSCG00000004596

LIPC

Lipase C, hepatic type

0.75

ENSSSCG00000015716

MARCO

Macrophage receptor with collagenous structure

0.73

ENSSSCG00000001459

HLA-DOB

MHC class II, DO beta

0.73

ENSSSCG00000001131

BTN2A2

Butyrophilin subfamily 2 member A2

0.68

ENSSSCG00000022230

CD9

CD9 molecule

0.60

ENSSSCG00000036050

CD302

CD302 molecule

0.54

ENSSSCG00000015413

FGL2

Fibrinogen like 2

ENSSSCG00000028855

GMPS

Guanine monophosphate synthase

−0.32
−0.47

0.56

ENSSSCG00000004918

ALPK2

Alpha kinase 2

ENSSSCG00000033919

DCLK1

Doublecortin like kinase 1

−0.47

ENSSSCG00000039770

SLC6A9

Solute carrier family 6 member 9

−0.69

ENSSSCG00000000688

LAG3

Lymphocyte activating 3

−0.76

ENSSSCG00000007748

PSPH

Phosphoserine phosphatase

−0.77

ENSSSCG00000027302

PKP3

Plakophilin 3

−0.79

ENSSSCG00000024015

FADS1

Fatty acid desaturase 1

−0.84

ENSSSCG00000005713

PLPP7

Phospholipid phosphatase 7 (inactive)

−0.84

There was a total of 98 differentially expressed genes that were unique to the MLV-129p-IFNmix group. The table represents some of the genes that may be key to understanding the
effects of the novel vaccine on potential markers of drug efficacy, metabolism, and anti-inflammatory immune responses (FDR ≤ 0.1).

in immunomodulation and viral immune evasion (27). The
downregulation around LAG3 is intriguing when viewed from
the perspective that the difference in the liver response between
vaccines may involve T-cell exhaustion. The phenomenon of
T-cell exhaustion is thought to result from persistent signaling
during chronic viral illness and cancers, which seems to be
partly driven by LAG3 upregulation. It is possible that LAG3
downregulation may reduce inhibition of a particular type of
T-cell response to PRRSV infection in pigs vaccinated with MLV129p-IFNmix. It may be that the downregulation of the LAG3
inhibitory signaling keeps T-cell proliferation and activation at
a metabolically sustainable level. In humans, overexpression of
LAG3 is correlated with disease progression in viral infections.
Downregulation may allow for less suppression surrounding
regulatory T-cells, but limit CD8 or CD4 T-cells. Another gene
uniquely expressed by the novel vaccine is, fibrinogen like 2
(FGL2) (Table 3); it is in the same gene family as FGL1, a major
ligand and co-activator of LAG3’s inhibitory action (18, 22).
Porcine FGL1 may not downregulate LAG3 action, but rather
upregulate FGL2, thereby negatively regulating dendritic cell,
memory T-cells, and macrophage antigen processing. However,

Frontiers in Veterinary Science | www.frontiersin.org

FGL2 does support T-cell activation on MHC molecules (18,
22, 28, 29). There was also unique macrophage (M2) gene
expression. Action of the gene FGL2 on macrophages in concert
with effector actions on regulatory T-cell expression has been
observed to promote repair among macrophages, possibly in
response to chronic illness or inflammation. The novel vaccine
might improve macrophage, T-cell, and pro-inflammatory
balance or may sort infected macrophages (needing opsonization
or phagocytosis) from uninfected. Reduced expression may
keep T-cell proliferation and activation at a metabolically
sustainable level, improving the efficiency of established immune
checkpoints against PRRSV.

CONCLUSION
Each vaccine elicited distinct patterns of gene transcription in
the liver of infected pigs. As compared to pigs administered
the commercial vaccine, those administered the novel MLV129p-IFNmix vaccine had fewer genes in flux at 14 dpi.
They may therefore have been experiencing less viralinduced stress on the organ/immune system. Compared
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